AAC Holdings, Inc. (AAC) Expected to Announce Quarterly Sales of $73.81 Million
Wall Street brokerages expect that AAC Holdings, Inc. (NYSE:AAC) will report $73.81 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for AAC’s earnings. The lowest sales estimate is $73.60 million and the highest is $74.03 million. AAC posted sales of $72.35 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 2%. The business is expected to announce its next earnings report on Monday, February 26th.
On average, analysts expect that AAC will report full year sales of $73.81 million for the current year, with estimates ranging from $305.10 million to $305.53 million. For the next financial year, analysts expect that the business will report sales of $342.98 million per share, with estimates ranging from $325.50 million to $360.47 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AAC.
AAC (NYSE:AAC) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $80.42 million during the quarter, compared to analysts’ expectations of $74.49 million. AAC had a positive return on equity of 9.64% and a negative net margin of 0.42%. The company’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.19 EPS.
In other AAC news, Chairman Michael T. Cartwright sold 250,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $9.63, for a total value of $2,407,500.00. Following the sale, the chairman now directly owns 2,880,490 shares of the company’s stock, valued at $27,739,118.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director W Larry Cash purchased 10,000 shares of the stock in a transaction on Thursday, November 30th. The stock was acquired at an average cost of $9.07 per share, for a total transaction of $90,700.00. Following the completion of the acquisition, the director now owns 25,000 shares of the company’s stock, valued at approximately $226,750. The disclosure for this purchase can be found here. Company insiders own 37.30% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in AAC. San Francisco Sentry Investment Group CA acquired a new stake in AAC in the 2nd quarter valued at about $31,241,000. EAM Investors LLC acquired a new stake in shares of AAC during the 3rd quarter worth approximately $1,977,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of AAC during the 3rd quarter worth approximately $456,000. Goldman Sachs Group Inc. purchased a new position in shares of AAC during the 1st quarter worth approximately $216,000. Finally, GSA Capital Partners LLP purchased a new position in shares of AAC during the 3rd quarter worth approximately $190,000. Institutional investors own 42.58% of the company’s stock.
AAC (NYSE AAC) traded down $0.14 on Friday, reaching $8.48. The company’s stock had a trading volume of 210,600 shares, compared to its average volume of 133,532. AAC has a fifty-two week low of $5.99 and a fifty-two week high of $13.06. The company has a market cap of $206.87, a price-to-earnings ratio of 13.26 and a beta of 1.95. The company has a debt-to-equity ratio of 1.42, a current ratio of 3.28 and a quick ratio of 3.28.
AAC Holdings, Inc is a provider of inpatient and outpatient substance abuse treatment services for individuals with drug and alcohol addiction. The Company performs drug testing and diagnostics laboratory services and provides physician services to its clients. As of June 30, 2016, the Company operated 12 residential substance abuse treatment facilities located throughout the United States, focused on delivering clinical care and treatment solutions across 1,139 beds, which includes 636 licensed detoxification beds, and 18 standalone outpatient centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AAC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AAC and related companies with MarketBeat.com's FREE daily email newsletter.